Partially randomized, non-blinded trial of DNA and MVA therapeutic vaccines based on hepatitis B virus surface protein for chronic HBV infection.
BACKGROUND: Chronic HBV infects 350 million people causing cancer and liver failure. We aimed to assess the safety and efficacy of plasmid DNA (pSG2.HBs) vaccine, followed by recombinant modified vaccinia virus Ankara (MVA.HBs), encoding the surface antigen of HBV as therapy for chronic HBV. A secon...
Những tác giả chính: | Cavenaugh, J, Awi, D, Mendy, M, Hill, A, Whittle, H, McConkey, S |
---|---|
Định dạng: | Journal article |
Ngôn ngữ: | English |
Được phát hành: |
Public Library of Science
2011
|
Những quyển sách tương tự
-
Partially randomized, non-blinded trial of DNA and MVA therapeutic vaccines based on hepatitis B virus surface protein for chronic HBV infection.
Bằng: James S Cavenaugh, et al.
Được phát hành: (2011-02-01) -
Safety, immunogenicity, and efficacy results of a phase II trial of therapeutic vaccines for chronic HBV in the Gambia.
Bằng: McConkey, S, et al.
Được phát hành: (2004) -
Therapeutic vaccination against hepatitis B virus using heterolgous prime boost strategy with DNA and modified vaccinia virus ankara vectors
Bằng: McConkey, S, et al.
Được phát hành: (2003) -
Synergistic DNA-MVA prime-boost vaccination regimes for malaria and tuberculosis.
Bằng: Gilbert, S, et al.
Được phát hành: (2006) -
Novel oligonucleotide assay detects HBV pre-core and basal core mutations in HBV-infected Gambians
Bằng: Mendy, M, et al.
Được phát hành: (2006)